About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

RECRUITINGNCT06774729

Development of a Radiomics Model With MR to Predict the Occurence of a Infiltration of Muscoskeletal Tumor

The goal of this observational study is to evaluate the feasibility and clinical utility of radiomics to diagnose peri-lesion tumour infiltration of tumours in participants with a suspect of Bone Canc...

Lead sponsor: IRCCS Azienda Ospedaliero-Universitaria di Bologna•1 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Clareo turns complex medical information into clear understanding you can use.

Bring this clarity to your next appointment.

Keep all your medical notes and next steps in one place.

Contacts

Vincenzo Lucidi, MD

CONTACT

+39 3385246923 vincenzo.lucidi@aosp.bo.it

Sponsors

Lead Sponsor

IRCCS Azienda Ospedaliero-Universitaria di Bologna

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Age over 18
•suspect of soft tissue sarcoma with a indication for surgical treatment
•suspect of bone cancer tumor with a indication for surgical treatment
•To give informed consent

Exclusion Criteria

•simultaneous cancer or history of cancer in the last 5 years
•acute or chronic serious conditions that could
•contraindication to conduct a Contrast-enhanced magnetic resonance imaging (MRI) such as:
•* renal failure without dialysis
•* history of allergy to a paramagnetic contrast agent
•* claustrophobia
•* symptomatic epilepsy or history of epilepsy
•* cardiac pacemaker
•* infusion pump, prosthesis or any implant not compatible with MRI
•* pregnancy

Related studies

Precision Medicine Approaches for Neoadjuvant Therapy in High-risk Sarcoma Patients

NCT07432932 · Sarcoma, Sarcoma, Leiomyo-, Adult, and more

RECRUITINGPhase 1/2

A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)

NCT05824975 · Advanced Solid Tumor, Metastatic Solid Tumor, and more

Not Yet RecruitingEARLY Phase 1

5-AminoLevulinic Acid Aided Resection Margins in Sarcoma

NCT07038278 · Soft Tissue Sarcoma (STS)

Not Yet RecruitingNA

Improved Management of Soft Tissue Sarcomas Patients With an Optimized and Innovative Sorting Technology for Circulating Tumor Cells

NCT07401355 · Diagnosis of Soft Tissue Sarcoma (STS)

Not Yet RecruitingPhase 2

A Prospective, Multicenter, Open-label, Single-arm Phase II Clinical Study Evaluating the Efficacy and Safety of Spatially Fractionated Radiotherapy Combined With the PraG Strategy for the Treatment of Soft Tissue Sarcoma

NCT07342322 · Soft Tissue Sarcoma (STS)

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: January 14, 2025Terms

Trial snapshot

StatusRECRUITING

Phase—

Enrollment122

Start dateMar 2025

Last updatedJan 14, 2025

Condition

Soft Tissue Sarcoma (STS)Bone Cancer Tumor

Locations shown

IRCCS Azienda Ospedaliero-Universitaria di Bologna

Bologna

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 14, 2025Data synced to Clareo: April 28, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions